Amendments to the Claims

1-6. (Cancelled)

7. (Currently amended) A compound of the formula (I):



(I)

wherein X is hydroxy ~~or optionally substituted amino~~;

Y is $-C(=R^2)-R^3-R^4$ wherein R^2 is oxygen atom or sulfur atom, R^3 is oxygen atom, sulfur atom or $N-R^5$, R^4 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted aralkyl and R^5 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl or optionally substituted aralkyl, or R^4 and R^5 may be taken together with the adjacent nitrogen atom to form optionally substituted non-aromatic heterocyclic group;

$-S(=O)_q-R^6-R^7$ wherein R^6 is oxygen atom or $N-R^7$, R^7 each is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted aralkyl and q is 1 or 2;

$-S(=O)_q-R^8$ wherein R^8 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted aralkyl and q is as defined above;

$-P(=O)(OR^9)_2$ wherein R^9 each is independently hydrogen or optionally substituted alkyl;

halogenated alkyl; or

optionally substituted heteroaryl;

Z is hydrogen or optionally substituted aralkyl;

Z^1 and Z^3each is independently a bond, alkylene or alkenylene;

Z^2 is alkylene, alkenylene, -CH(OH)-, -S-, -SO-, $-SO_2-$, $-SO_2NR^{10}-$, $-NR^{10}SO_2-$, -O-, $-NR^{10}-$, $-NR^{10}CO-$, $-CONR^{10}-$, -C(=O)-O-, -O-C(=O)- or -CO-;

R^{10} is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted aralkyl;

R^1 is optionally substituted branched alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted non-aromatic heterocyclic group, optionally substituted aryl or optionally substituted heteroaryl;

p is 1 to 2, provided that when p is 2, the groups of the formula: $-Z^1-Z^2-Z^3-R^1$are different from each other;

ring (A) is optionally substituted aromatic heterocycle; and

the group of the formula: -C(Z)=C(X)Y in the formula (I) substitutes at an atom adjacent to a hetero atom in ring (A), a tautomer of itself, a pharmaceutically acceptable salt thereof or a solvate thereof.

8. (Currently amended) The compound according to claim 7 wherein Y is optionally substituted heteroaryl; and wherein the group of the formula: -C(Z)=C(X)- in the formula (I) substitutes at an atom adjacent to a hetero atom in Y ~~the heteroaryl is combined with an atom adjacent to a hetero atom in Y,~~ a tautomer of itself, a pharmaceutically acceptable salt thereof or a solvate thereof.

9. (Previously presented) The compound according to claim 7 wherein X is hydroxy;

Y is $-C(=R^2)-R^3-R^4$ wherein R^2 is oxygen atom, R^3 is oxygen atom or $N-R^5$, R^4 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted aralkyl and R^5 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl or optionally substituted aralkyl, or R^4 and R^5 may be taken

together with the adjacent nitrogen atom to form optionally substituted non-aromatic heterocyclic group;

optionally substituted tetrazolyl; optionally substituted triazolyl; optionally substituted thiazolyl; optionally substituted isoxazolyl; optionally substituted pyrazinyl; optionally substituted imidazolyl; optionally substituted pyrimidinyl or optionally substituted pyridyl, a tautomer of itself, a pharmaceutically acceptable salt thereof or a solvate thereof.

10. (Previously presented) The compound according to claim 7 wherein ring (A) is optionally substituted aromatic heterocycle containing nitrogen atom, a tautomer of itself, a pharmaceutically acceptable salt thereof or a solvate thereof.

11. (Previously presented) The compound according to claim 7 wherein ring (A) is optionally substituted pyridine, optionally substituted pyrazine, optionally substituted pyrimidine, optionally substituted oxazole, optionally substituted thiadiazole, optionally substituted quinoline, optionally substituted isoquinoline, optionally substituted purine, optionally substituted benzoxazole or optionally substituted benzimidazole, a tautomer of itself, a pharmaceutically acceptable salt thereof or a solvate thereof.

12. (Previously presented) The compound according to claim 7 wherein Z^2 is alkylene or -O-, a tautomer of itself, a pharmaceutically acceptable salt thereof or a solvate thereof.

13. (Previously presented) The compound according to claim 7 wherein Z^1 and Z^3 each is independently a bond or alkylene and R^1 is optionally substituted branched alkyl, optionally substituted cycloalkyl, optionally substituted non-aromatic heterocyclic group, optionally substituted aryl or optionally substituted heteroaryl, a tautomer of itself, a pharmaceutically acceptable salt thereof or a solvate thereof.

14. (Previously presented) The compound according to claim 7 wherein Z^1 is a bond; Z^2 is alkylene or -O-; Z^3 is a bond or alkylene; and ring (A) is optionally substituted pyridine, a tautomer of itself, a pharmaceutically acceptable salt thereof or a solvate thereof.

15-16. (Cancelled)

17. (Withdrawn-Currently amended) A pharmaceutical composition which comprises as an active ingredient the compound according to any one of claims 7 to 14 ~~15~~, a tautomer of itself, a pharmaceutically acceptable salt thereof or a solvate thereof, and a pharmaceutically acceptable carrier or diluent.

18. (Withdrawn-Currently amended) A pharmaceutical composition useful for an anti-viral agent which comprises as an active ingredient the compound according to any one of claims 7 to 14 ~~15~~, a tautomer of itself, a pharmaceutically acceptable salt thereof or a solvate thereof, and a pharmaceutically acceptable carrier or diluent.

19. (Withdrawn-Currently amended) A pharmaceutical composition useful for an anti-HIV agent which comprises as an active ingredient the compound according to any one of claims 7 to 14 ~~15~~, a tautomer of itself, a pharmaceutically acceptable salt thereof or a solvate thereof, and a pharmaceutically acceptable carrier or diluent.

20. (Withdrawn-Currently amended) A pharmaceutical composition having an integrase-inhibiting activity which comprises as an active ingredient the compound according to any one of claims 7 to 14 ~~15~~, a tautomer of itself, a pharmaceutically acceptable salt thereof or a solvate thereof, and a pharmaceutically acceptable carrier or diluent.

21. (Withdrawn) An anti-HIV medical mixture which comprises a reverse transcriptase inhibitor and/or a protease inhibitor in addition to the compound according to claim 7.

22. (Withdrawn) The anti-HIV medical mixture according to claim 21 which enhances an anti-HIV activity of a reverse transcriptase inhibitor and/or a protease inhibitor.

23. (Withdrawn) A method for treating AIDS or AIDS-related complication which comprises administering an effective amount of the compound according to claim 7 to a patient in need thereof.

24. (Cancelled)